Longitudinal evaluation of environmental contamination with hazardous drugs by surface wipe sampling.

CSTD Hazardous drugs compounding pharmacy preparation surface contamination

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
19 Dec 2023
Historique:
medline: 20 12 2023
pubmed: 20 12 2023
entrez: 20 12 2023
Statut: aheadofprint

Résumé

Exposure of healthcare workers to hazardous drugs can lead to adverse health effects supporting the importance of a continuous monitoring program, for example, by taking surface wipe samples. The objective was to describe the results of repeated monitoring of contamination with hazardous drugs on multiple surfaces in a hospital pharmacy and at two wards using standardized preparation techniques and cleaning procedures. Twelve surfaces in the hospital pharmacy and at two wards were sampled and analyzed for contamination with the hazardous drugs cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, methotrexate, and paclitaxel. The drugs were prepared with a closed-system drug transfer device (CSTD). Sampling of the drugs was performed in four trials during eight months. Liquid chromatography tandem mass spectrometry was used for the analysis of the drugs. During the four trials, contamination with five of the six hazardous drugs was found on half of the surfaces in the pharmacy and in a ward. Seventeen out of 288 possible outcomes were positive (6%), with the biological safety cabinet grate ( The long-term use of a CSTD in combination with appropriate cleaning has proven effective in achieving low levels of surface contamination with hazardous drugs.

Identifiants

pubmed: 38115732
doi: 10.1177/10781552231205481
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10781552231205481

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Paul Jm Sessink (PJ)

Exposure Control Sweden AB, Bohus-Björkö, Sweden.

Birgit Tans (B)

Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

Isabel Spriet (I)

Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

David Devolder (D)

Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

Classifications MeSH